Literature DB >> 29270065

Adult chronic myelomonocytic leukemia with trisomy 11: a case report.

S H Yoo1, J Lim2, J M Byun3, J H Park3, K H Kim3, I S Choi3.   

Abstract

Chronic myelomonocytic leukemia (cmml) is an indolent disease in the category of myelodysplastic and myeloproliferative neoplasms, which can often evolve into acute leukemic neoplasms. Although cytogenetic abnormalities such as trisomy 8 or absence of chromosome Y are well known, few reports about cmml with trisomy 11 have been published. Here, we report a case of cmml with trisomy 11 as the sole chromosomal abnormality, resulting in a very poor outcome. Based on a bone marrow specimen, cmml-1 with trisomy 11 was diagnosed in a 79-year-old man presenting with anemia and atypical peripheral blood cells. Because of the patient's age, he was followed without receiving anticancer treatment. Two months after his diagnosis, the patient's leucocytosis and anemia rapidly worsened, with increasing numbers of immature peripheral cells, which was strongly suggestive of leukemic transformation. Because of acute kidney injury superimposed on chronic kidney disease that led to poor performance status, cytotoxic chemotherapy was not considered feasible, and the patient was transferred to a hospice care facility.

Entities:  

Keywords:  Myelodysplastic syndrome; case reports; chronic myelomonocytic leukemia; trisomy 11

Year:  2017        PMID: 29270065      PMCID: PMC5736495          DOI: 10.3747/co.24.3738

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  15 in total

1.  Trisomy 11: prevalence among 22,403 unique patient cytogenetic studies and clinical correlates.

Authors:  D Caramazza; R P Ketterling; R A Knudson; C A Hanson; S Siragusa; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2010-04-01       Impact factor: 11.528

Review 2.  Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-06       Impact factor: 10.047

3.  A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Authors:  Eric Padron; Amy Dezern; Marcio Andrade-Campos; Kris Vaddi; Peggy Scherle; Qing Zhang; Yan Ma; Maria E Balasis; Sara Tinsley; Hanadi Ramadan; Cassandra Zimmerman; David P Steensma; Gail J Roboz; Jeffrey E Lancet; Alan F List; Mikkael A Sekeres; Rami S Komrokji
Journal:  Clin Cancer Res       Date:  2016-02-08       Impact factor: 12.531

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Authors:  Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl
Journal:  Blood       Date:  2007-08-28       Impact factor: 22.113

6.  Trisomy 11 in myelodysplasia.

Authors:  R Morgan; M H Greene; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1988-01

7.  Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

Authors:  Emnet A Wassie; Raphael Itzykson; Terra L Lasho; Olivier Kosmider; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Eric Solary; Ayalew Tefferi; Mrinal M Patnaik
Journal:  Am J Hematol       Date:  2014-09-26       Impact factor: 10.047

8.  Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.

Authors:  A-K Eisfeld; J Kohlschmidt; K Mrózek; J S Blachly; D Nicolet; K Kroll; S Orwick; A J Carroll; R M Stone; A de la Chapelle; J C Byrd; C D Bloomfield
Journal:  Leukemia       Date:  2016-07-20       Impact factor: 12.883

9.  Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012.

Authors:  Eun-Hye Park; Hyewon Lee; Young-Joo Won; Hee Young Ju; Chang-Mo Oh; Cecile Ingabire; Hyun-Joo Kong; Byung-Kiu Park; Ju Young Yoon; Hyeon-Seok Eom; Eunyoung Lee; Hyeon Jin Park
Journal:  Blood Res       Date:  2015-12-21

Review 10.  Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.

Authors:  M M Patnaik; A Tefferi
Journal:  Blood Cancer J       Date:  2016-02-05       Impact factor: 11.037

View more
  1 in total

1.  Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?

Authors:  Jan Philipp Bewersdorf; Rory M Shallis; Autumn Diadamo; Lohith Gowda; Nikolai A Podoltsev; Alexa Siddon; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2020-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.